Literature DB >> 26714658

Alzheimer disease. Donepezil and nursing home placement--benefits and costs.

Vesna Jelic1, Bengt Winblad1.   

Abstract

The recent DOMINO-AD trial suggests that continued treatment with donepezil delays nursing home placement for patients with severe Alzheimer disease, but more work is needed to support strong conclusions about whether the benefits outweigh the costs.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26714658     DOI： 10.1038/nrneurol.2015.237

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  9 in total

1.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

Authors:  C Courtney; D Farrell; R Gray; R Hills; L Lynch; E Sellwood; S Edwards; W Hardyman; J Raftery; P Crome; C Lendon; H Shaw; P Bentham
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

2.  Long-term effects of Alzheimer's disease treatment.

Authors:  Anders Wimo
Journal:  Lancet Neurol       Date:  2015-10-27       Impact factor: 44.182

3.  Comparison of prescription drug use between community-dwelling and institutionalized elderly in Sweden.

Authors:  Kristina Johnell; Johan Fastbom
Journal:  Drugs Aging       Date:  2012-09       Impact factor: 3.923

4.  Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.

Authors:  Robert Howard; Rupert McShane; James Lindesay; Craig Ritchie; Ashley Baldwin; Robert Barber; Alistair Burns; Tom Dening; David Findlay; Clive Holmes; Robert Jones; Roy Jones; Ian McKeith; Ajay Macharouthu; John O'Brien; Bart Sheehan; Edmund Juszczak; Cornelius Katona; Robert Hills; Martin Knapp; Clive Ballard; Richard G Brown; Sube Banerjee; Jessica Adams; Tony Johnson; Peter Bentham; Patrick P J Phillips
Journal:  Lancet Neurol       Date:  2015-10-27       Impact factor: 44.182

5.  Variation in antipsychotic treatment choice across US nursing homes.

Authors:  Krista F Huybrechts; Kenneth J Rothman; M Alan Brookhart; Rebecca A Silliman; Stephen Crystal; Tobias Gerhard; Sebastian Schneeweiss
Journal:  J Clin Psychopharmacol       Date:  2012-02       Impact factor: 3.153

Review 6.  EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.

Authors:  R Schmidt; E Hofer; F H Bouwman; K Buerger; C Cordonnier; T Fladby; D Galimberti; J Georges; M T Heneka; J Hort; J Laczó; J L Molinuevo; J T O'Brien; D Religa; P Scheltens; J M Schott; S Sorbi
Journal:  Eur J Neurol       Date:  2015-03-25       Impact factor: 6.089

7.  Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients.

Authors:  Kristina Johnell; Dorota Religa; Maria Eriksdotter
Journal:  Dement Geriatr Cogn Disord       Date:  2013-03-07       Impact factor: 2.959

Review 8.  Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.

Authors:  Anders Wimo
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  Cholinesterase inhibitors for Alzheimer's disease.

Authors:  J Birks
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25
  9 in total
  6 in total

Review 1.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

2.  What Can We Learn About Mental Health Needs From Tweets Mentioning Dementia on World Alzheimer's Day?

Authors:  Sunmoo Yoon
Journal:  J Am Psychiatr Nurses Assoc       Date:  2016-11       Impact factor: 2.385

3.  Vascular biomarkers to predict response to exercise in Alzheimer's disease: the study protocol.

Authors:  Danni Li; Robin Thomas; Michael Y Tsai; Ling Li; David M Vock; Susan Greimel; Fang Yu
Journal:  BMJ Open       Date:  2016-12-30       Impact factor: 2.692

4.  Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.

Authors:  Hong Xu; Sara Garcia-Ptacek; Linus Jönsson; Anders Wimo; Peter Nordström; Maria Eriksdotter
Journal:  Neurology       Date:  2021-03-19       Impact factor: 9.910

Review 5.  A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.

Authors:  William James Deardorff; George T Grossberg
Journal:  Drug Des Devel Ther       Date:  2016-10-03       Impact factor: 4.162

6.  Medial septum tau accumulation induces spatial memory deficit via disrupting medial septum-hippocampus cholinergic pathway.

Authors:  Dongqin Wu; Di Gao; Haitao Yu; Guilin Pi; Rui Xiong; Huiyang Lei; Xin Wang; Enjie Liu; Jinwang Ye; Huilin Yu; Yang Gao; Ting He; Tao Jiang; Fei Sun; Jingfen Su; Guoda Song; Wenju Peng; Ying Yang; Jian-Zhi Wang
Journal:  Clin Transl Med       Date:  2021-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.